Twin Capital Management Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 19.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,264 shares of the company’s stock after selling 16,802 shares during the period. Johnson & Johnson accounts for 1.4% of Twin Capital Management Inc.’s holdings, making the stock its 9th largest holding. Twin Capital Management Inc.’s holdings in Johnson & Johnson were worth $10,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently modified their holdings of the company. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after purchasing an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P grew its holdings in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares during the last quarter. AMI Investment Management Inc. grew its holdings in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares during the last quarter. Equitable Holdings Inc. grew its holdings in shares of Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd grew its holdings in shares of Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after purchasing an additional 20,528 shares during the last quarter. 67.57% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 in the last quarter. 0.20% of the stock is owned by company insiders.
Analyst Ratings Changes
Johnson & Johnson Stock Down 0.3 %
JNJ stock opened at $172.92 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The company has a market capitalization of $449.41 billion, a price-to-earnings ratio of 35.00, a PEG ratio of 2.92 and a beta of 0.54. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The stock has a fifty day moving average of $165.50 and a 200-day moving average of $161.20.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter in the prior year, the company earned $2.59 EPS. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 10.75 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.75%. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- What is a Bond Market Holiday? How to Invest and Trade
- On Holding Slips Into A More Comfortable Price PointÂ
- How to Invest in Blue Chip Stocks
- 3 Growing Cannabis Stocks Ready To Bloom
- What Are Utility Stocks? An Overview of the Utilities Sector
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
